公开(公告)号：BR112021015238A8

公开(公告)日：2022-08-16

申请号：BR112021015238

申请日：2020-01-30

Applicant: LAVA THERAPEUTICS B V ,  LAVA THERAPEUTICS N V

Inventor： JOHANNES JELLE VAN DER VLIET ,  IRIS DE WEERDT ,  TANJA DENISE DE GRUIJL ,  PAUL PARREN ,  ARON PHILIP KATER ,  GEORGE LODEWIJK SCHEFFER

IPC: C07K16/28 ,  A61P35/00

Abstract: NOVOS ANTICORPOS DE LIGAÇÃO A CD40. A presente invenção se refere a novos anticorpos capazes de se ligar a CD40 humano e a novos anticorpos multiespecíficos capazes de se ligar a CD40 humano e de se ligar a um receptor de células T V¿9V¿2 humano. A invenção também se refere a composições farmacêuticas que compreendem os anticorpos da invenção e aos usos dos anticorpos da invenção para tratamento médico.

公开(公告)号：CA3128148A1

公开(公告)日：2020-08-06

申请号：CA3128148

申请日：2020-01-30

Applicant: LAVA THERAPEUTICS B V

Inventor： VAN DER VLIET JOHANNES JELLE ,  DE WEERDT IRIS ,  DE GRUIJL TANJA DENISE ,  PARREN PAUL ,  KATER ARON PHILIP ,  SCHEFFER GEORGE LODEWIJK

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human V?9Vd2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

公开(公告)号：CA3113605A1

公开(公告)日：2020-03-26

申请号：CA3113605

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B V

Inventor： DE WEERDT IRIS ,  KATER ARNON PHILIP ,  PARREN PAUL WILLEM HENRI IDA ,  DE GRUIJL TANJA DENISE ,  VAN DER VLIET JOHANNES JELLE ,  LAMERIS ROELAND

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/04

Abstract: The present invention relatestonovel methodsfor the treatment of hematological malignancies. In particular, the invention relatesto the treatment of hematological malignancies using antibodiescomprising a first binding moiety that is able to bind human CD1d and a second binding moiety that is able to bind the human V?9Vd2-TCR.

公开(公告)号：BR112021005184A8

公开(公告)日：2022-08-16

申请号：BR112021005184

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B V ,  LAVA THERAPEUTICS N V

Inventor： JOHANNES JELLE VAN DER VLIET ,  ROELAND LAMERIS ,  TANJA DENISE DE GRUIJL ,  PAUL WILLEM HENRI IDA PARREN

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/04

Abstract: IMUNOGLOBULINA CD1D DE DUPLA AÇÃO. A presente invenção se refere ao campo da imunologia, mais em particular ao campo das frações de ligação e/ou imunoglobulinas que se ligam a CD1d humano, incluindo anticorpos e fragmentos dos mesmos que modificam funções biológicas mediadas por CD1d, como ativação intensificada e ativação reduzida de células T restritas a CD1d, incluindo as células T exterminadoras naturais e células T gamadelta, e modulação da função de células que expressam Cd1d. A invenção também se refere a imunoglobulinas bi-, tri ou multiespecíficas que se ligam a CD1d e a um TCR gama-delta e/ou um alvo tumoral. A invenção refere-se adicionalmente a preparações farmacêuticas e uso de tais unidades de ligação mono-, bi-, e tri- ou multiespecíficas e/ou imunoglobulinas no tratamento de doenças ou distúrbios.

公开(公告)号：SG11202102629WA

公开(公告)日：2021-04-29

申请号：SG11202102629W

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B V

Inventor： VAN DER VLIET JOHANNES JELLE ,  LAMERIS ROELAND ,  DE GRUIJL TANJA DENISE ,  PARREN PAUL WILLEM HENRI IDA

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/04

Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T-cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri- or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-, and tri- or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.

公开(公告)号：AU2016212777A1

公开(公告)日：2017-08-17

申请号：AU2016212777

申请日：2016-01-27

Applicant: LAVA THERAPEUTICS B V

Inventor： VAN DER VLIET JOHANNES JELLE ,  DE GRUIJL TANJA DENISE ,  VERHEUL HENDRIK MARINUS WILLEM ,  DE BRUIN RENEE CORNELIA GERARDA ,  LAMERIS ROLAND

IPC: C07K16/28

Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.

公开(公告)号：SG11202108141VA

公开(公告)日：2021-08-30

申请号：SG11202108141V

申请日：2020-01-30

Applicant: LAVA THERAPEUTICS B V

Inventor： VAN DER VLIET JOHANNES JELLE ,  DE WEERDT IRIS ,  DE GRUIJL TANJA DENISE ,  PARREN PAUL ,  KATER ARON PHILIP ,  SCHEFFER GEORGE LODEWIJK

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

公开(公告)号：SG10202007233TA

公开(公告)日：2020-09-29

申请号：SG10202007233T

申请日：2015-04-10

Applicant: LAVA THERAPEUTICS B V

Inventor： VAN DER VLIET JOHANNES JELLE ,  DE BRUIN RENÉE CORNELIA GERARDA ,  DE GRUIJL TANJA DENISE ,  VERHEUL HENDRIK MARINUS WILLEM

Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated.

公开(公告)号：MX2017009680A

公开(公告)日：2018-04-13

申请号：MX2017009680

申请日：2016-01-27

Applicant: LAVA THERAPEUTICS B V

Inventor： RENÉE CORNELIA GERARDA DE BRUIN ,  TANJA DENISE DE GRUIJL ,  HENDRIK MARINUS WILLEM VERHEUL ,  ROELAND LAMERIS ,  JOHANNES JELLE VAN DER VLIET

IPC: C07K16/28

Abstract: La invención está relacionada a compuesto, en particular a polipéptidos que se unen específicamente a la proteína MHC no clásica CD1d y modulan las funciones biológicas mediadas por CD1d; la invención en particularmente relacionada a tales compuestos y polipéptidos que comprenden o consisten en al menos un anticuerpo de dominio simple se une específicamente a CD1d; también se proporcionan métodos y el uso empleando tales compuestos, polipéptidos y/o anticuerpos de dominio simple.

公开(公告)号：BR112021015238A2

公开(公告)日：2022-02-15

申请号：BR112021015238

申请日：2020-01-30

Applicant: LAVA THERAPEUTICS B V

Inventor： ARON PHILIP KATER ,  GEORGE LODEWIJK SCHEFFER ,  IRIS DE WEERDT ,  JOHANNES JELLE VAN DER VLIET ,  PARREN PAUL ,  TANJA DENISE DE GRUIJL

IPC: C07K16/28 ,  A61P35/00

Abstract: novos anticorpos de ligação a cd40. a presente invenção se refere a novos anticorpos capazes de se ligar a cd40 humano e a novos anticorpos multiespecíficos capazes de se ligar a cd40 humano e de se ligar a um receptor de células t v¿9v¿2 humano. a invenção também se refere a composições farmacêuticas que compreendem os anticorpos da invenção e aos usos dos anticorpos da invenção para tratamento médico.